Literature DB >> 23299818

Increased local cytokine production at culprit superficial femoral artery plaques.

Cameron W Donaldson1, David J Schneider, Daniel J Bertges, Julie E Adams, Nader Z Elgharib, Enkhtuyaa L Mueller, William Prabhu, Taka Ashikaga, Harold L Dauerman.   

Abstract

Characterization of local inflammation at culprit superficial femoral artery (SFA) stenosis has not been studied. We hypothesized that arterial cytokine concentrations would be greater at sites of stenosis. Twenty patients with ≥50 % angiographic stenosis of the SFA had blood drawn just proximal to the lesion and from a contralateral site free of disease. A microplate immunoassay was used to determine the concentrations of 42 distinct cytokines and growth factors. Exact conditional logistic analysis was used to compare measures at the two sites with interaction terms describing clinical factors used to identify difference mediators. Interaction terms identified clinical factors that could predict cytokine levels. The concentrations of soluble CD40 ligand (sCD40L; mean 212 and 177 pg/ml, p = 0.01) and tumor necrosis factor beta (TNF-B; mean 16.6 and 15.9 pg/ml, p = 0.04) were increased immediately proximal to areas of stenosis. Factors associated with greater concentrations at sites of stenosis were bilateral ankle-brachial index ≤0.90 (p = 0.04), no statin use (p = 0.02), claudication (p = 0.03), low leukocyte count (p = 0.03), absence of limb ischemia (p = 0.04) and lack of aspirin or clopidogrel therapy (p ≤ 0.06). Greater concentrations of sCD40L and TNF-B at sites of stenosis suggest that these cytokines play a role in the pathogenesis of symptomatic SFA disease. Our results also suggest that statin, aspirin and clopidogrel therapy may attenuate localized inflammation in the SFA, though due to a small sample size and the use of multiple comparisons across groups, these findings can be viewed as hypothesis generating only. In conclusion, selected cytokines are heightened at culprit SFA lesions and inflammation may be modulated by statin and antiplatelet therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299818     DOI: 10.1007/s11239-012-0860-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  33 in total

1.  Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk.

Authors:  Aruna D Pradhan; Sanjay Shrivastava; Nancy R Cook; Nader Rifai; Mark A Creager; Paul M Ridker
Journal:  Circulation       Date:  2008-01-28       Impact factor: 29.690

2.  Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study.

Authors:  Hannes Franz Alber; Matthias Frick; Alois Suessenbacher; Jakob Doerler; Michael Schirmer; Eva-Maria Stocker; Wolfgang Dichtl; Otmar Pachinger; Franz Weidinger
Journal:  Am Heart J       Date:  2006-01       Impact factor: 4.749

3.  Peripheral artery disease, biomarkers, and darapladib.

Authors:  Jeffrey S Berger; Christie M Ballantyne; Michael H Davidson; Joel L Johnson; Elizabeth A Tarka; Denise Lawrence; Trupti Trivedi; Andrew Zalewski; Emile R Mohler
Journal:  Am Heart J       Date:  2011-05       Impact factor: 4.749

4.  The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients.

Authors:  Seung Hwan Han; Kwang Kon Koh; Michael J Quon; Yonghee Lee; Eak Kyun Shin
Journal:  Atherosclerosis       Date:  2006-02-28       Impact factor: 5.162

5.  Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.

Authors:  Valerio Sanguigni; Pasquale Pignatelli; Luisa Lenti; Domenico Ferro; Alfonso Bellia; Roberto Carnevale; Manfredi Tesauro; Roberto Sorge; Renato Lauro; Francesco Violi
Journal:  Circulation       Date:  2005-02-01       Impact factor: 29.690

6.  C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes.

Authors:  Lavinia Forte; Giovanni Cimmino; Francesco Loffredo; Raffaele De Palma; Gianfranco Abbate; Paolo Calabrò; Diego Ingrosso; Patrizia Galletti; Ciro Carangio; Beniamino Casillo; Raffaele Calabrò; Paolo Golino
Journal:  Int J Cardiol       Date:  2011-07-26       Impact factor: 4.164

7.  Circulating CD40 ligand is elevated only in patients with more advanced symptomatic peripheral arterial diseases.

Authors:  Wen-Jane Lee; Wayne Huey-Herng Sheu; Ying-Tsung Chen; Tsun-Jui Liu; Kae-Woei Liang; Chih-Tai Ting; Wen-Lieng Lee
Journal:  Thromb Res       Date:  2005-12-13       Impact factor: 3.944

Review 8.  Intermittent claudication: an overview.

Authors:  Ashwinkumar V Meru; Shivani Mittra; Baskaran Thyagarajan; Anita Chugh
Journal:  Atherosclerosis       Date:  2005-12-28       Impact factor: 5.162

9.  Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting.

Authors:  Atul Aggarwal; David J Schneider; Burton E Sobel; Harold L Dauerman
Journal:  Am J Cardiol       Date:  2003-10-15       Impact factor: 2.778

10.  Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction.

Authors:  H Suzuki; T Kusuyama; R Sato; Y Yokota; F Tsunoda; T Sato; M Shoji; Y Iso; S Koba; T Katagiri
Journal:  Eur J Clin Invest       Date:  2008-03       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.